On November 20, 2026, Merck reported that its Phase 3 TroFuse-015 trial met its primary endpoint:
sacituzumab tirumotecan (sac-TMT) significantly and meaningfully improved overall survival versus treatment chosen by physicians.
The trial enrolled 473 people with locally advanced, unresectable or metastatic gastroesophageal adenocarcinoma—including gastric, gastroesophageal-junction and esophageal cancers—after at least two prior lines of systemic therapy.
The comparison treatments included trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Merck said the survival benefit was generally consistent across subgroups, regardless of TROP2 expression.
There were caveats:
sac-TMT did not meet the secondary progression-free-survival endpoint. Response rates nominally favored sac-TMT, but that result was not formally tested under the study’s analysis plan.
Merck said no new safety concerns emerged. Detailed results have not yet been released; the company plans to present them at a future medical meeting. TroFuse-015 is the second positive Phase 3 result reported in Merck’s TroFuse program.
Sources:
Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trial
Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer
Merck TROP2 ADC Meets Survival End Point in Gastroesophageal Cancer | BioPharm International
Merck’s drug prolongs survival in advanced stomach, esophageal cancers in trial
MSD’s ADC gains OS win but PFS miss in Phase III stomach cancer trial
Merck Phase 3 Trial Shows Survival Benefit in Advanced Cancer
Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial
Why Is Merck Stock Trading Higher Today? - Merck & Co (NYSE:MRK)